02196 FOSUN PHARMA
- 14.300
- -0.020-0.14%
FOSUN PHARMA News
Shanghai Fosun Pharmaceutical (Group) Unit's Cervical Dystonia Gets NMPA Nod
Fosun Pharma Gets Marketing Authorization for Botox Injection
Fosun Pharma Gains Approval for New Drug in China
Fosun Pharma (02196) announced that its major shareholder Fosun Technology has released the pledge of 0.12 billion shares.
Fosun Pharma (02196) announced that it received a notification from its controlling shareholder on November 27, 2024...
Express News | Shanghai Fosun Pharma - Nda of Botulinum Toxin Type a for Injection Approved by Nmpa
Fosun Pharma (02196.HK) spent HKD 4.1039 million on November 27 to repurchase 0.2875 million shares.
Gelonghui reported on November 27 that fosun pharma (02196.HK) announced that on November 27, 2024, it spent 4.1039 million Hong Kong dollars to repurchase 0.2875 million shares, with a repurchase price of 14.06-14.44 Hong Kong dollars per share.
fosun pharma (600196.SH): Licensed products obtain pharmaceutical registration approval.
On November 27, Gelonghui reported that Fosun Pharma (600196.SH) announced that its holding subsidiary Shanghai Fosun Pharma Industrial Development Co., Ltd. has received approval from the National Medical Products Administration for the marketing authorization application of injectable type A botulinum toxin (trademark in China: Daxifei, project code: RT002) for the treatment of adult cervical dystonia.
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Can Mixed Fundamentals Have A Negative Impact on Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Current Share Price Momentum?
Hong Kong stocks concept tracking | The commercialization trend of surgical siasun robot&automation is obvious, and the prospect of domestic substitution is broad (with concept stocks)
Over 30,000 kilometers, the siasun robot&automation's remote surgery in china once again achieved a breakthrough.
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
Fosun pharma (02196.HK) spent 1.8 million HKD to repurchase 128,000 shares on November 25.
On November 25th, Gelonhui announced that fosun pharma (02196.HK) issued a notice to repurchase 0.128 million shares for 1.8 million Hong Kong dollars on November 25, 2024, at a repurchase price of 14-14.1 Hong Kong dollars per share.
Shanghai Fosun Pharma Moves Forward With Henlius Merger
Bullish market stimulation boosts Hong Kong healthcare stocks, causing Lai Kai Pharmaceuticals to surge over 18%.
①What bullish news about pharmaceutical stocks has recently been announced in the market? ②How do institutions view the subsequent performance of pharmaceutical stocks?
Jiuyuan Genomics (02566.HK) is expected to be listed on November 28, with multiple cornerstone investors including fosun pharma.
Genomics Nine Limited (02566.HK) has announced that the company plans to globally offer 45.3988 million H shares, with 4.54 million shares to be offered in Hong Kong, and 40.8588 million shares to be offered internationally; the IPO will take place from November 20 to November 25, 2024, with the expected pricing date being November 26; the offer price will be between HK$11.48 and HK$12.56 per share, with a trading unit of 200 shares per board lot; Huatai International is the sole sponsor; the anticipated shares will commence trading on the Stock Exchange of Hong Kong on November 28, 2024.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.
①At the earnings conference, fosun pharma indicated that due to the continued expansion of innovative drugs and other factors, the company's performance in Q3 improved year-on-year. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the prompt market entry of injectable type A botulinum toxin in china. ③ The privatization process of henlius and the accessibility of CAR-T products have also attracted significant attention.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Hong Kong stock concept tracking | Peking expands the scope of medical insurance reimbursement for hematopoietic stem cell transplantation. Stem cell-related pharmaceutical companies benefit (with concept stocks)
Peking Municipal Medical Insurance Bureau: Expanding the scope of medical insurance reimbursement for hematopoietic stem cell transplantation.
Analysis
Price Target
No Data
No Data